These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 19780704

  • 1. Darinaparsin: a novel organic arsenical with promising anticancer activity.
    Mann KK, Wallner B, Lossos IS, Miller WH.
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1727-34. PubMed ID: 19780704
    [Abstract] [Full Text] [Related]

  • 2. A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines.
    Diaz Z, Mann KK, Marcoux S, Kourelis M, Colombo M, Komarnitsky PB, Miller WH.
    Leukemia; 2008 Oct; 22(10):1853-63. PubMed ID: 18633430
    [Abstract] [Full Text] [Related]

  • 3. Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line.
    Matulis SM, Morales AA, Yehiayan L, Croutch C, Gutman D, Cai Y, Lee KP, Boise LH.
    Mol Cancer Ther; 2009 May; 8(5):1197-206. PubMed ID: 19417148
    [Abstract] [Full Text] [Related]

  • 4. Chemical and clinical development of darinaparsin, a novel organic arsenic derivative.
    Quintás-Cardama A, Verstovsek S, Freireich E, Kantarjian H, Chen YW, Zingaro R.
    Anticancer Agents Med Chem; 2008 Dec; 8(8):904-9. PubMed ID: 19075572
    [Abstract] [Full Text] [Related]

  • 5. The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models.
    Ravi D, Bhalla S, Gartenhaus RB, Crombie J, Kandela I, Sharma J, Mazar A, Evens AM.
    Clin Cancer Res; 2014 Dec 01; 20(23):6023-33. PubMed ID: 25316819
    [Abstract] [Full Text] [Related]

  • 6. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
    Douer D, Tallman MS.
    J Clin Oncol; 2005 Apr 01; 23(10):2396-410. PubMed ID: 15800332
    [Abstract] [Full Text] [Related]

  • 7. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
    Amadori S, Fenaux P, Ludwig H, O'dwyer M, Sanz M.
    Curr Med Res Opin; 2005 Mar 01; 21(3):403-11. PubMed ID: 15811209
    [Abstract] [Full Text] [Related]

  • 8. Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer.
    Tian J, Zhao H, Nolley R, Reese SW, Young SR, Li X, Peehl DM, Knox SJ.
    Clin Cancer Res; 2012 Jun 15; 18(12):3366-76. PubMed ID: 22535156
    [Abstract] [Full Text] [Related]

  • 9. Arsenicals in hematologic cancers.
    Novick SC, Warrell RP.
    Semin Oncol; 2000 Oct 15; 27(5):495-501. PubMed ID: 11049017
    [Abstract] [Full Text] [Related]

  • 10. Darinaparsin is a multivalent chemotherapeutic which induces incomplete stress response with disruption of microtubules and Shh signaling.
    Mason TA, Kolobova E, Liu J, Roland JT, Chiang C, Goldenring JR.
    PLoS One; 2011 Oct 15; 6(11):e27699. PubMed ID: 22110729
    [Abstract] [Full Text] [Related]

  • 11. S-Dimethylarsino-glutathione (darinaparsin®) targets histone H3.3, leading to TRAIL-induced apoptosis in leukemia cells.
    Xu X, Wang H, Li H, Hu X, Zhang Y, Guan X, Toy PH, Sun H.
    Chem Commun (Camb); 2019 Oct 29; 55(87):13120-13123. PubMed ID: 31616884
    [Abstract] [Full Text] [Related]

  • 12. Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies.
    Tallman MS.
    Blood Rev; 2001 Sep 29; 15(3):133-42. PubMed ID: 11735161
    [No Abstract] [Full Text] [Related]

  • 13. A phase I clinical trial of darinaparsin in patients with refractory solid tumors.
    Tsimberidou AM, Camacho LH, Verstovsek S, Ng C, Hong DS, Uehara CK, Gutierrez C, Daring S, Stevens J, Komarnitsky PB, Schwartz B, Kurzrock R.
    Clin Cancer Res; 2009 Jul 15; 15(14):4769-76. PubMed ID: 19584162
    [Abstract] [Full Text] [Related]

  • 14. The novel arsenical darinaparsin is transported by cystine importing systems.
    Garnier N, Redstone GG, Dahabieh MS, Nichol JN, del Rincon SV, Gu Y, Bohle DS, Sun Y, Conklin DS, Mann KK, Miller WH.
    Mol Pharmacol; 2014 Apr 15; 85(4):576-85. PubMed ID: 24431147
    [Abstract] [Full Text] [Related]

  • 15. Darinaparsin inhibits prostate tumor-initiating cells and Du145 xenografts and is an inhibitor of hedgehog signaling.
    Bansal N, Farley NJ, Wu L, Lewis J, Youssoufian H, Bertino JR.
    Mol Cancer Ther; 2015 Jan 15; 14(1):23-30. PubMed ID: 25381261
    [Abstract] [Full Text] [Related]

  • 16. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
    Verstovsek S, Giles F, Quintás-Cardama A, Perez N, Ravandi-Kashani F, Beran M, Freireich E, Kantarjian H.
    Hematol Oncol; 2006 Dec 15; 24(4):181-8. PubMed ID: 16783836
    [Abstract] [Full Text] [Related]

  • 17. Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors.
    Kuo CC, Liu TW, Chen LT, Shiah HS, Wu CM, Cheng YT, Pan WY, Liu JF, Chen KL, Yang YN, Chen SN, Chang JY.
    Free Radic Biol Med; 2011 Dec 15; 51(12):2195-209. PubMed ID: 22001324
    [Abstract] [Full Text] [Related]

  • 18. Arsenic trioxide in the management of acute promyelocytic leukaemia.
    Mathews V, Chandy M, Srivastava A.
    Natl Med J India; 2001 Dec 15; 14(4):215-22. PubMed ID: 11547528
    [Abstract] [Full Text] [Related]

  • 19. Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea.
    Ogura M, Kim WS, Uchida T, Uike N, Suehiro Y, Ishizawa K, Nagai H, Nagahama F, Sonehara Y, Tobinai K.
    Jpn J Clin Oncol; 2021 Feb 08; 51(2):218-227. PubMed ID: 33051668
    [Abstract] [Full Text] [Related]

  • 20. Arsenic trioxide: safety issues and their management.
    Au WY, Kwong YL.
    Acta Pharmacol Sin; 2008 Mar 08; 29(3):296-304. PubMed ID: 18298894
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.